{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:47:45Z","timestamp":1782809265559,"version":"3.54.5"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:45:48Z","timestamp":1778546748000},"page":"1300-1312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial"],"prefix":"10.1016","volume":"85","author":[{"given":"Edward","family":"Vital","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michelle","family":"Kahlenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Arriens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Catlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coburn","family":"Hobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ard.2026.02.007_bib0001","first-page":"330","article-title":"Manifestations of systemic lupus erythematosus","volume":"6","author":"Cojocaru","year":"2011","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.ard.2026.02.007_bib0002","article-title":"Inflammatory cytokines in systemic lupus erythematosus","volume":"2011","author":"Ohl","year":"2011","journal-title":"J Biomed Biotechnol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.007_bib0003","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.007_bib0004","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","article-title":"Systemic lupus erythematosus pathogenesis: interferon and beyond","volume":"41","author":"Caielli","year":"2023","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.007_bib0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41423-018-0010-6","article-title":"Type I interferons promote the survival and proinflammatory properties of transitional B cells in systemic lupus erythematosus patients","volume":"16","author":"Liu","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.007_bib0006","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203308090020","article-title":"The innate immune system in SLE: type I interferons and dendritic cells","volume":"17","author":"R\u00f6nnblom","year":"2008","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.ard.2026.02.007_bib0007","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.02.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: innate immune responses propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.ard.2026.02.007_bib0009","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/ard-2023-225349","article-title":"Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology","volume":"83","author":"Carter","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0010","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"issue":"502","key":"10.1016\/j.ard.2026.02.007_bib0011","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.ard.2026.02.007_bib0012","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ard.2026.02.007_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16021","article-title":"Transancestral mapping and genetic load in systemic lupus erythematosus","volume":"8","author":"Langefeld","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ard.2026.02.007_bib0015","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.3390\/ijms24043391","article-title":"Tyk2 targeting in immune-mediated inflammatory diseases","volume":"24","author":"Rusi\u00f1ol","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ard.2026.02.007_bib0016","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1093\/rheumatology\/keac625","article-title":"Deep stratification by transcriptome molecular characters for precision treatment of patients with systemic lupus erythematosus","volume":"62","author":"Qiao","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2026.02.007_bib0017","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ard.2026.02.007_bib0018","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.007_bib0019","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2026.02.007_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cyto.2018.03.041","article-title":"The regulation of JAKs in cytokine signaling and its breakdown in disease","volume":"118","author":"Hammar\u00e9n","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.ard.2026.02.007_bib0021","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.ard.2026.02.007_bib0022","series-title":"Prescribing information","year":"2026"},{"key":"10.1016\/j.ard.2026.02.007_bib0023","series-title":"Product monograph","year":"2022"},{"key":"10.1016\/j.ard.2026.02.007_bib0024","series-title":"Australian product information","year":"2022"},{"key":"10.1016\/j.ard.2026.02.007_bib0025","series-title":"Product information","year":"2022"},{"issue":"Suppl 9","key":"10.1016\/j.ard.2026.02.007_bib0026","article-title":"Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study [Abstract 1000]","volume":"74","author":"Kahlenberg","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.007_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100291","article-title":"Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study","volume":"20","author":"Guthridge","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.ard.2026.02.007_bib0028","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/art.40653","article-title":"Stratification of systemic lupus erythematosus patients into three groups of disease activity progression according to longitudinal gene expression","volume":"70","author":"Toro-Dom\u00ednguez","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0029","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1038\/s41467-021-24584-w","article-title":"Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data","volume":"12","author":"Altman","year":"2021","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.ard.2026.02.007_bib0030","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/bioinformatics\/btab121","article-title":"BloodGen3Module: blood transcriptional module repertoire analysis and visualization using R","volume":"37","author":"Rinchai","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ard.2026.02.007_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-1-0716-0327-7_19","article-title":"Cell-type enrichment analysis of bulk transcriptomes using xCell","volume":"2120","author":"Aran","year":"2020","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ard.2026.02.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.108953","article-title":"Systemic lupus erythematosus as a genetic disease","volume":"236","author":"Harley","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ard.2026.02.007_bib0033","article-title":"Advanced methods and novel biomarkers in autoimmune diseases a review of the recent years progress in systemic lupus erythematosus","volume":"10","author":"Fenton","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.ard.2026.02.007_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079217","article-title":"A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity","volume":"8","author":"Tarca","year":"2013","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.ard.2026.02.007_bib0035","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1093\/nar\/gks461","article-title":"Camera: a competitive gene set test accounting for inter-gene correlation","volume":"40","author":"Wu","year":"2012","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.ard.2026.02.007_bib0036","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.4049\/jimmunol.1501740","article-title":"TGF-beta-induced regulatory T cells directly suppress B cell responses through a noncytotoxic mechanism","volume":"196","author":"Xu","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0037","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-024-03327-4","article-title":"Unraveling transcriptomic signatures and dysregulated pathways in systemic lupus erythematosus across disease states","volume":"26","author":"Wang","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.02.007_bib0038","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","article-title":"Targeting plasma cells in systemic autoimmune rheumatic diseases - promises and pitfalls","volume":"260","author":"Steinmetz","year":"2023","journal-title":"Immunol Lett"},{"issue":"5","key":"10.1016\/j.ard.2026.02.007_bib0039","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.41187","article-title":"B cell tetherin: a flow cytometric cell-specific assay for response to type I interferon predicts clinical features and flares in systemic lupus erythematosus","volume":"72","author":"El-Sherbiny","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-023-03089-5","article-title":"Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil","volume":"25","author":"Akthar","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.007_bib0041","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/bjd\/ljad089","article-title":"Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers","volume":"189","author":"Carter","year":"2023","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.007_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.ard.2026.02.007_bib0043","series-title":"Prescribing information","year":"2025"},{"issue":"2","key":"10.1016\/j.ard.2026.02.007_bib0044","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/ard-2024-226051","article-title":"Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways","volume":"84","author":"Moysidou","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.02.007_bib0045","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard-2023-224795","article-title":"Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort","volume":"83","author":"Parodis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.02.007_bib0046","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/ard-2024-225664","article-title":"Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events","volume":"83","author":"Nikolopoulos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.007_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1121359","article-title":"Transcriptome sequencing reveals novel molecular features of SLE severity","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Genet"},{"issue":"11","key":"10.1016\/j.ard.2026.02.007_bib0048","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1101\/pdb.top084970","article-title":"RNA sequencing and analysis","volume":"2015","author":"Kukurba","year":"2015","journal-title":"Cold Spring Harb Protoc"},{"issue":"5","key":"10.1016\/j.ard.2026.02.007_bib0049","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrg.2016.10","article-title":"Translating RNA sequencing into clinical diagnostics: opportunities and challenges","volume":"17","author":"Byron","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"10","key":"10.1016\/j.ard.2026.02.007_bib0050","first-page":"575","article-title":"Emerging concepts of type I interferons in SLE pathogenesis and therapy","volume":"18","author":"Psarras","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0051","doi-asserted-by":"crossref","first-page":"bbaf031","DOI":"10.1093\/bib\/bbaf031","article-title":"Cell-type deconvolution for bulk RNA-seq data using single-cell reference: a comparative analysis and recommendation guideline","volume":"26","author":"Xu","year":"2024","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.ard.2026.02.007_bib0052","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","article-title":"Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"J Mol Diagn"},{"issue":"Suppl 9","key":"10.1016\/j.ard.2026.02.007_bib0053","article-title":"Development of an IFN 5-gene signature score to identify IFN-high and IFN-low subsets and as a pharmacodynamic biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus [Abstract 0847]","volume":"75","author":"Wu","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 9","key":"10.1016\/j.ard.2026.02.007_bib0054","article-title":"Four-year safety and efficacy of deucravacitinib in systemic lupus erythematosus: results from a phase 2 program [Abstract LB10]","volume":"77","author":"Morand","year":"2025","journal-title":"Arthritis Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:34:03Z","timestamp":1782808443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0003496726000828"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.007","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}